Pramiracetam

From Wikipedia, the free encyclopedia - View original article

Pramiracetam
Pramiracetam.svg
Pramiracetam3d.png
Systematic (IUPAC) name
N-[2-(diisopropylamino)ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide
Clinical data
Trade namesNeupramir, Pramistar, Remen
AHFS/Drugs.comInternational Drug Names
Legal statusUnscheduled (US)
RoutesOral
Pharmacokinetic data
Half-life4.5-6.5 hours
Identifiers
CAS number68497-62-1 N
ATC codeN06BX16
PubChemCID 51712
ChemSpider46801 YesY
UNII4449F8I3LE YesY
ChEMBLCHEMBL159776 YesY
Chemical data
FormulaC14H27N3O2 
Mol. mass269.383 g/mol
 N (what is this?)  (verify)
 
Jump to: navigation, search
Pramiracetam
Pramiracetam.svg
Pramiracetam3d.png
Systematic (IUPAC) name
N-[2-(diisopropylamino)ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide
Clinical data
Trade namesNeupramir, Pramistar, Remen
AHFS/Drugs.comInternational Drug Names
Legal statusUnscheduled (US)
RoutesOral
Pharmacokinetic data
Half-life4.5-6.5 hours
Identifiers
CAS number68497-62-1 N
ATC codeN06BX16
PubChemCID 51712
ChemSpider46801 YesY
UNII4449F8I3LE YesY
ChEMBLCHEMBL159776 YesY
Chemical data
FormulaC14H27N3O2 
Mol. mass269.383 g/mol
 N (what is this?)  (verify)

Pramiracetam is a nootropic drug derived from piracetam, and is more potent (i.e. lower dosage is used)[citation needed]. It belongs to the racetam family of nootropics, and goes by the trade name Remen (Parke-Davis), Neupramir (Lusofarmaco) or Pramistar (Firma).[1] Pramiracetam is used off-label for a wide range of applications.

History[edit]

Pramiracetam was developed by Parke-Davis in the late 1970s. The first patents for this drug appeared in 1978 (Belgium) and 1979 (US), concurrent with its first reporting of nootropic characteristics.

Side effects[edit]

Pramiracetam, like other members of the racetam family, is generally well tolerated by humans[citation needed]. In a study where a small sample of human subjects with varying degrees of Alzheimer's disease were treated for 5–8 weeks, symptoms were few and mild. At relatively low dosages, a few participants reported headaches. One participant at the highest end of the dosage spectrum experienced sleepiness, decreased appetite, and dizziness[citation needed]. In another study where a small sample of healthy, male human subjects were treated for 10 days, no adverse events were reported.[2][citation needed]

References[edit]

  1. ^ Axel Kleemann, Jürgen Engel, Bernd Kutscher und Dietmar Reichert: Pharmaceutical Substances, 4. Edition (2000), ISBN 978-1-58890-031-9
  2. ^ "Pramiracetam: Smarter Nootropics". March 30, 2012. Retrieved April 11, 2012. 

External links[edit]